rf-fullcolor.png

 

September 11, 2025
by Jason Scott

Recon: Prasad regains FDA chief medical and scientific officer title; FDA panel to review AI mental health devices

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

In Focus: US
  • Vaccine policy threatens to put Kennedy at odds with Trump (STAT)
  • Dropping hepatitis B shots for newborns would ignore history and endanger children, scientists warn (STAT)
  • AbbVie shares hit record high as key immunology drug set for exclusivity until 2037 (Reuters) (Pharmaphorum)
  • J&J claims FDA okay for bladder cancer drug TAR-200 (Pharmaphorum)
  • Intercept pulls liver disease drug from market as FDA puts clinical trials on hold (Endpoints)
  • Vinay Prasad regains role as FDA chief medical officer (Reuters)
  • How RFK Jr. Is Pushing the CDC to the Brink (Bloomberg)
  • RFK Jr.'s 'historic changes' to drug ads would trigger range of ripple effects (Endpoints)
In Focus: International
  • EU Critical Medicines Act: Parliament Clarifies ‘Significant Proportion’ Rule (Pink Sheet)
  • Pharma says UK is 'tumbling down' rankings for investment (Pharmaphorum)
  • Fresh blow to UK life sciences as MSD abandons £1bn project (Pharmaphorum)
  • Argentina's Milei vetoes pediatric hospitals funding law (Reuters)
  • Congo’s Ebola Virus Outbreak Seen Posing Major Threat to Angola (Bloomberg)
Pharma & Biotech
  • Child dies after receiving new experimental gene therapy (STAT)
  • Psychedelics are suddenly drawing interest from big drugmakers (STAT)
  • Piercing the hype around Patrick Soon-Shiong’s ‘Bioshield’ cancer treatment (STAT)
  • Zentiva set to change hands in €4.1bn private equity deal (Pharmaphorum)
  • Q&A: Lasker Award winner Michael Welsh on the science that led to life-saving cystic fibrosis drugs (Endpoints)
  • Avidity shares fall after $500M offering, dimming hopes of a Novartis buyout (Endpoints)
  • Maze’s SLC6A19 inhibitor moves to Phase 2; GenFleet to go public in Hong Kong (Endpoints)
  • Exclusive: Sophont raises $9.2M to build multimodal foundation models (Endpoints)
  • Novo Nordisk tells staff to return to office full-time amid CEO's revival effort (Reuters)
  • Merck's pneumococcal shot shows promise in at-risk children and teens (Reuters)
Medtech
  • FDA will convene an advisory committee to tackle AI mental health device regulation (STAT) (Reuters)
  • Patients call for more medical device user fee funding, FDA staffing (MedTech Dive)
  • GE HealthCare inks Icometrix buyout to acquire brain MRI software (MedTech Dive)
  • Masimo, Philips extend patient monitoring partnership (MedTech Dive)
Food & Nutrition
  • The MAHA kids’ health report missed an important opportunity on children and non-sugar sweeteners (STAT)
  • Can Eating Only Meat on a Carnivore Diet Be a Good Thing? (Bloomberg)
Government, Regulatory & Legal  
  • Eli Lilly loses appeal of $183.7 million Medicaid fraud award (Reuters)
  • HPM Fact Sheet: Ensuring FDA and HHS Are Held Accountable For “Radical Transparency” and Communicating Truthful and Non-Misleading Information About DTC Rx Drug Ad “Crackdown” (FDA Law Blog)
  • SEC files charges against former FibroGen CMO for manipulating clinical trial data (Endpoints)
  • Just 1 in 4 Americans think vaccine policy shifts are based on science, Reuters/Ipsos poll finds (Reuters)
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.
 
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.